Publications

Selected Publications

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial
Jama Oncology
JAMA Oncol. 2024 Feb 15:e236789.   doi: 10.1001/jamaoncol.2023.6789   Peter W Szlosarek 1 2 3, Benjamin C Creelan 4, Thomas Sarkodie 2, Luke Nolan 5, Paul Taylor 6, Olga Olevsky 7, Federica Grosso 8, Diego Cortinovis 9, Meenali Chitnis 10, Amy Roy 11, David Gilligan 12, Hedy Kindler 13, Dionysis Papadatos-Pastos 14, Giovanni ...
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
Singh, A. et al. Oncogene 42, 572-585 (2023).
Accelerating innovations in systemic therapy for pleural mesothelioma
Fennell, D. A. & Bzura, A. Nat Cancer 3, 902-904 (2022).
Immunotherapy approaches for malignant pleural mesothelioma.
Fennell, D. A., Dulloo, S. & Harber, J. Nat Rev Clin Oncol 19, 573-584 (2022).
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
Fennell, D. A. et al. EClinicalMedicine 48, 101432 (2022).
The Lancet Oncology
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Zauderer, M. G. et al. Lancet Oncol 23, 758-767 (2022).
The Lancet Oncology
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Kindler, H. L. et al.. Lancet Oncol 23, 540-552 (2022).
The Lancet Oncology
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
Fennell, D. A. et al. Lancet Oncol 23, 374-381 (2022).
The Lancet Oncology
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Fennell, D. A. et al. Lancet Oncol 22, 1530-1540 (2021).
NE Journal of Medicine
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes, S. M., Alrifai, D. & Fennell, D. A. N Engl J Med 385, 1207-1218 (2021).
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Zhang, M. et al. Nat Commun 12, 1751 (2021).
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
The Lancet
Scagliotti, G. V. et al. Lancet Respir Med 7, 569-580 (2019).
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature
PubMed ID: 28445469
The Lancet Oncology
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
The Lancet
Maio, M. et al. Lancet Oncol 18, 1261-1273 (2017).
Novel insights into mesothelioma biology and implications for therapy
Nature Reviews Cancer
Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Nat Rev Cancer 17, 475-488 (2017)
The Lancet Oncology
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
The Lancet
Krug, L. M. et al. Lancet Oncol 16, 447-456 (2015).